LEE SPENCER S

EVP Lee Spencer sells 1,500 CHE shares at $577.99; 3 of 3 measurable prior CHE sells well-timed with negative 90d returns

EVP Lee Spencer sold 1,500 shares (9.3% of pre-transaction holdings) at $577.99 on 2025-05-16, reducing his position from 16,127 to 14,627 shares. His timing pattern at CHE is notable: his prior three measurable sales at this ticker (2024-11-22, 2024-08-08, and 2024-03-28) all showed negative 90-day returns of -2.8%, -5.2%, and -15.6% respectively, indicating the sales preceded declines. Cross-ticker, his broader track record shows 7 prior sells with a 60.00% well-timed rate at the 90-day mark. The current price of $578.02 sits 6.6% below the 52-week high, and the stock is up 5.0% over 90 days, suggesting Spencer may be executing ahead of potential pullback risk based on his demonstrated pattern at this ticker.

EVP Lee Spencer sells 1,500 CHE shares for $866.8K; stock down 8.1% from 52-week high

Lee Spencer S, executive vice president of Chemed Corp, sold 1,500 shares at $577.86 on 2025-05-07, reducing holdings from 17,627 to 16,127 shares (-8.5%). The sale occurred with CHE trading at -8.1% from its 52-week high of $619.21, placing the transaction in the lower end of the recent range. Spencer's prior trades at CHE show mixed timing outcomes: 3 of 4 measurable 90-day periods were well-timed (stock declined post-sale), but his most recent sale on 2025-03-03 was followed by +3.8% 30-day returns, suggesting the timing advantage does not hold consistently at this ticker. With the company trading at a P/E of 26.97 on $8.3B market cap and posting $646.9M quarterly revenue with +7.4% annual growth, the sale does not occur during an obvious fundamental deterioration.

Lee Spencer S (EVP, CHE) sold 1.3K shares at $592.25 on 2025-03-03; holds 17.6K post-transaction.

Lee Spencer S, executive vice president of Chemed Corp, sold 1,326 shares for $785,323.50 on 2025-03-03, reducing his holdings from 19.0K to 17.6K shares. Among his five prior sales at CHE, three demonstrated negative 90-day returns (the most recent in 2024-11-22 showing -7.5% at 30 days and -2.8% at 90 days), suggesting some pattern of well-timed exits at this ticker. The stock is currently trading at $591.27, within its 52-week range of $517.44–$650.70 and 9.1% below its high; the sale occurred at $592.25. This modest position reduction—a 7.0% decrease in holdings—occurs within a moderately valued company (P/E 26.13, market cap $8.7B) with solid recent fundamentals (revenue $606.2M latest quarter, net income $75.8M, annual revenue growth +7.4%).

EVP Lee Spencer S sells 1,000 CHE shares at $565.71; holds 19.0K post-transaction. Stock -3.7% in 30d.

Lee Spencer S, executive vice president of CHEMED CORP, sold 1,000 shares at $565.71 on 2024-11-22, reducing holdings to 19.0K shares (a -5.0% reduction from 20.0K). The current price of $570.96 reflects recent weakness: the stock is -3.7% over 30 days and -0.2% over 90 days, trading 12.2% below its 52-week high of $650.70. His same-ticker history shows mixed execution: two of his four prior CHE sales were followed by 90-day declines (2024-08-08 and 2024-03-28), while two were followed by modest gains. His cross-ticker track record shows 4 prior sales with an average 90-day return of -4.2% and a 50% well-timed rate. This sale occurs in a period of stock softness but does not constitute a large reduction in his 19.0K remaining position relative to his continued ownership stake.

LEE SPENCER S sold 1,016 shares of CHE at $580.48; holds 20,019 shares post-transaction

LEE SPENCER S, executive vice president of CHEMED CORP, sold 1,016 shares at $580.48 on 2024-08-08, reducing his holdings from 21,035 to 20,019 shares (a -4.8% reduction). The sale occurred at a price near current levels ($580.06) and within the 52-week range; the stock has risen +9.9% over the prior 30 days. His cross-ticker track record shows 3 prior open-market sells with an average 90-day return of -3.9% and a 33.33% well-timed rate, while his prior sales at CHE itself (3 trades) have been mixed: one strongly well-timed with -15.6% 90-day return (2024-03-28), one flat to slightly positive (2023-11-27 and 2023-11-07). The modest position reduction and recent positive price momentum do not indicate a coordinated or substantial conviction shift; the company itself reports solid fundamentals with $595.9M quarterly revenue, +6.1% annual growth, and $70.9M net income.